India · Delayed Price · Currency is INR CORONA Remedies Statistics
Total Valuation
CORONA Remedies has a market cap or net worth of INR 131.04 billion. The enterprise value is 132.40 billion.
| Market Cap | 131.04B |
| Enterprise Value | 132.40B |
Important Dates
The last earnings date was Friday, July 31, 2026.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | Jun 19, 2026 |
Share Statistics
| Current Share Class | 61.16M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 69.00% |
| Owned by Institutions (%) | 7.11% |
| Float | 10.76M |
Valuation Ratios
The trailing PE ratio is 65.84 and the forward PE ratio is 50.67.
| PE Ratio | 65.84 |
| Forward PE | 50.67 |
| PS Ratio | 8.86 |
| PB Ratio | 17.55 |
| P/TBV Ratio | 27.07 |
| P/FCF Ratio | 236.75 |
| P/OCF Ratio | 57.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 42.19, with an EV/FCF ratio of 239.21.
| EV / Earnings | 66.52 |
| EV / Sales | 8.95 |
| EV / EBITDA | 42.19 |
| EV / EBIT | 48.04 |
| EV / FCF | 239.21 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 0.53 |
| Debt / FCF | 2.98 |
| Interest Coverage | 37.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 23.85% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 2.87M |
| Profits Per Employee | 386,241 |
| Employee Count | 5,153 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CORONA Remedies has paid 610.60 million in taxes.
| Income Tax | 610.60M |
| Effective Tax Rate | 23.48% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2,020.57 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 57.74 |
| Average Volume (20 Days) | 2,694 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CORONA Remedies had revenue of INR 14.79 billion and earned 1.99 billion in profits. Earnings per share was 32.55.
| Revenue | 14.79B |
| Gross Profit | 11.95B |
| Operating Income | 2.75B |
| Pretax Income | 2.60B |
| Net Income | 1.99B |
| EBITDA | 3.10B |
| EBIT | 2.75B |
| Earnings Per Share (EPS) | 32.55 |
Balance Sheet
The company has 288.30 million in cash and 1.65 billion in debt, with a net cash position of -1.36 billion.
| Cash & Cash Equivalents | 288.30M |
| Total Debt | 1.65B |
| Net Cash | -1.36B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 7.47B |
| Book Value Per Share | 122.12 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 2.29 billion and capital expenditures -1.74 billion, giving a free cash flow of 553.50 million.
| Operating Cash Flow | 2.29B |
| Capital Expenditures | -1.74B |
| Depreciation & Amortization | 347.26M |
| Net Borrowing | 773.80M |
| Free Cash Flow | 553.50M |
| FCF Per Share | n/a |
Margins
Gross margin is 80.82%, with operating and profit margins of 18.60% and 13.46%.
| Gross Margin | 80.82% |
| Operating Margin | 18.60% |
| Pretax Margin | 17.58% |
| Profit Margin | 13.46% |
| EBITDA Margin | 20.95% |
| EBIT Margin | 18.60% |
| FCF Margin | 3.94% |
Dividends & Yields
This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.47%.
| Dividend Per Share | 10.00 |
| Dividend Yield | 0.47% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.48% |
| Earnings Yield | 1.52% |
| FCF Yield | 0.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for CORONA Remedies is 2,304.67, which is 7.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 2,304.67 |
| Price Target Difference | 7.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 17.73% |
| EPS Growth Forecast (3Y) | 26.65% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |